期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 14, 期 28, 页码 4445-4453出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.14.4445
关键词
hepatocellular carcinoma; liver transplantation; liver resection; adjuvant therapy; salvage liver transplantation; radiofrequency ablation; transarterial chemoembolization
Liver resection (LR) and transplantation offer the only potential chance of cure for patients with hepatocellular carcinoma (HCC). Historically, all patients were treated by hepatic resection. With the advent of liver transplantation (LT) patients with HCC were preferentially placed on the waiting list for LT. However, early experience with LT was associated with a high rate of tumour recurrence and poor long-term survival. The increasing scarcity of donor livers resulted in restrictions being placed on tumour size, and an improvement in patient survival. To date there have been no randomised clinical trials comparing LR to LT. We review the evidence supporting LR and/or IT for HCC and discuss the role of neoadjuvant therapy. The decision of whether to resect or transplant remains debatable and is often determined by centre experience, availability of LT and donor organs. (C) 2008 The WJG Press. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据